300110.SHE Huaren Pharmaceutical Co Ltd
- Market cap
- CNY 3.00B
- P/E
- -
- P/B
- 3.47x
- ROE
- 4.1%
- Dividend yield
- 1.41%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300110.SHE undervalued?
Graham numberThe Graham number of Huaren Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Huaren Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Huaren Pharmaceutical Co Ltd yet.
Huaren Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and …
Full company profileHuaren Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Huaren Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.25B | 1.31B | 1.38B | 1.46B | 1.32B | 1.56B | 1.62B | 1.64B | 1.35B | 1.32B | 1.17B |
| Gross Profit | 558M | 694M | 794M | 820M | 555M | 760M | 696M | 696M | 468M | 490M | 368M |
| Operating Income | 32.2M | 63.8M | 47.8M | 74.0M | 114M | 151M | 198M | 226M | -1.35B | 168M | 104M |
| EBITDA | 210M | 229M | 200M | 206M | 236M | 348M | 425M | 422M | -1.18B | -309M | 92.9M |
| Net Income | 23.9M | 37.5M | 38.8M | 42.1M | 94.6M | 130M | 181M | 188M | -1.37B | -463M | 35.9M |
| EPS | 0.02 | 0.04 | 0.03 | 0.04 | 0.08 | 0.11 | 0.15 | 0.16 | -1.16 | -0.39 | 0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 2.72B | 2.89B | 3.15B | 2.71B | 3.42B | 5.64B | 5.16B | 5.17B | 3.43B | 2.70B | 2.71B |
| Total Liabilities | 1.20B | 1.34B | 897M | 462M | 1.09B | 3.20B | 2.56B | 2.40B | 2.05B | 1.79B | 1.77B |
| Shareholders' Equity | 1.46B | 1.49B | 2.18B | 2.18B | 2.26B | 2.37B | 2.53B | 2.69B | 1.30B | 838M | 865M |
| Cash & Short-term Investments | 30.2M | 149M | 617M | 382M | 229M | 417M | 222M | 232M | 164M | 139M | 233M |
| Total Debt | 858M | 967M | 717M | 202M | 537M | 2.03B | 1.92B | 1.46B | 888M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 182M | 211M | 254M | 309M | -10.7M | -579M | 218M | 306M | 322M | 390M | - |
| Capital Expenditure | 169M | 87.4M | 45.5M | 32.0M | 58.0M | 27.9M | 42.3M | 45.9M | 24.7M | 49.0M | 18.7M |
| Free Cash Flow | 12.7M | 124M | 209M | 277M | -68.7M | -606M | 176M | 260M | 298M | 341M | 152M |
| Ratios | |||||||||||
| ROE | 1.6% | 2.5% | 1.8% | 1.9% | 4.2% | 5.5% | 7.1% | 7.0% | -105.2% | -55.2% | 4.1% |
| ROA | 0.9% | 1.3% | 1.2% | 1.6% | 2.8% | 2.3% | 3.5% | 3.6% | -39.9% | -17.1% | 1.3% |
| Net Profit Margin | 1.9% | 2.9% | 2.8% | 2.9% | 7.2% | 8.4% | 11.2% | 11.5% | -101.1% | -35.0% | 3.1% |
| Debt to Equity | 0.59x | 0.65x | 0.33x | 0.09x | 0.24x | 0.86x | 0.76x | 0.54x | 0.68x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Huaren Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.41%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 10, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 42.5M | 0.04 | - |
| 2024 | CNY 78.9M | 0.07 | - |
| 2023 | CNY 86.1M | 0.07 | 45.8% |
| 2022 | CNY 21.3M | 0.02 | 11.8% |
| 2021 | CNY 17.7M | 0.01 | 13.6% |
| 2020 | CNY 11.8M | 0.01 | 12.5% |
| 2019 | CNY 35.5M | 0.03 | 84.3% |
| 2018 | CNY 55.6M | 0.05 | 143.2% |
| 2017 | CNY 49.9M | 0.05 | 133.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 31, 2017.
Who owns Huaren Pharmaceutical Co Ltd
- Insiders 38.77%
- Institutions 0.09%
- Public & others 61.15%
- Shares outstanding 1.18B
- Free float 879M
Huaren Pharmaceutical Co Ltd company profile
- Company name
- Huaren Pharmaceutical Co Ltd
- Ticker
- 300110.SHE
- ISIN
- CNE100000SW1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 25, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,549
- Fiscal year end
- December
- Address
- No. 187, Zhuzhou Road, Qingdao, China, 266101
- Phone
- 86 532 5807 0788
- Website
- qdhuaren.com
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of medicines and medical equipment in China and internationally. It offers nephrology products, including peritoneal dialysate, hemofiltration replacement fluid, and hemofiltration basic solution; respiratory products, such as doxofylline, levofloxacin hydrochloride, and composite potassium hydrogen phosphate injections; caffeine citrate injection; and bulk preparations comprising sodium chloride, glucose, glucose and sodium chloride, compound sodium chloride, sodium lactate ringer's, and compound electrolyte injections, as well as sterile water for injection and rinsing liquid products. The company also provides therapeutic infusion, which includes blood volume expander, haemostatic, nervous system, circulatory system, anti-infectives, anti-hepatitis and hepatitis adjuvant drugs, antineoplastic and adjuvant drugs, and glucose metabolism; and rubber stoppers. In addition, it is involved in software development; investment management; and construction. The company was founded in 1998 and is based in Qingdao, China.
Huaren Pharmaceutical Co Ltd management
4- Mr. Jian LinPresident · born 1982
- Ms. Liping HanVP & CFO · born 1985
- Mr. Xinguang FengVP & Secretary to the Board of Directors · born 1985
- Mr. Junhong WangVice President · born 1977